NEW YORK , Sept. 24, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI ), a leading developer of cellular therapies for neurodegenerative diseases, today announced the acceptance of two abstracts featuring NurOwn® (MSC-NTF or Debamestrocel) at the 2024 Annual Northeastern Amyotrophic Lateral Sclerosis Consortium (NEALS) Meeting , to take place October 21 - 24 , in-person in Clearwater, Florida and virtually.
"We look forward to sharing the latest update on NurOwn at this year's NEALS meeting. The insights and feedback that we gather from the ALS community are invaluable in advancing our mission to address the unmet needs of patients with this devastating disease," said Chaim Lebovits , President and CEO of BrainStorm. "Our top priority continues to be the initiation of a Phase 3b clinical trial, in order to confirm NurOwn's efficacy and conclusively demonstrate its efficacy in early stage ALS patients.
Our team is energized by the progress to date and is working diligently to ensure the execution and success of this important study. As we make preparations, we anticipate multiple key milestones in the coming months that we believe will have potential to drive value. We remain committed to advancing our novel treatment option for ALS patients and achieving regulatory approval as quickly as possible.
" Presentation details Title: Debamestrocel Long-Term Benefits on Survival and Neurodegeneration in ALS Expanded Access Program Lead Author: Bob Dagher, MD Sessi.